Negocios · 15/10/20121 min de lectura
Prospective Grant of Exclusive License: The Development of Anti-CD22 Chimeric Antigen Receptors (CARs) for the Treatment of B Cell Malignancies
Traducción automática local · Idioma original de la fuente
Resumen
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in (a) U.S. Patent Application 61/549,516 entitled "Anti-CD22 Chimeric Antigen Receptors" [HHS Ref. E-265-2011/0-US-01], and (b) U.S. Patent Application 60/325,360 [HHS Ref. E-129-2001/0-US-01], PCT Application PCT/US02/30316 [HHS Ref. E-129-2001/0-PCT-02], U.S. Patent 7,355,012 [HHS Ref. E-129-2001/0-US-03], European Patent 1448584 [HHS Ref. E-129- 2001/0-EP-04] (validated in Germany, Spain, France, The United Kingdom and Italy [HHS Ref. E-129-2001/0-IT-12], Australian Patent 2002327053 [HHS Ref. E-129-2001/0-AU-05], Canadian Patent Application 2461351 [HHS Ref. E-129-2001/0-CA-06], U.S. Patent 7,777,019 [HHS Ref. E-129-2001/0- US-07], U.S. Patent Application 12/846,625 [HHS Ref. E-129-2001/0-US- 13], U.S. Patent Application 13/438,725 [HHS Ref. E-129-2001/0-US-14] (all entitled "Mutated Anti-CD22 Antibodies with Increased Affinity to CD22 Expressing Leukemia Cells"), and all related continuing and foreign patents/patent applicati